Comparaison des bénéfices médico-économiques des antipsychotiques dans la prise en charge de la schizophrénie en France

This analysis, to the best of our knowledge, is the first of its kind to assess the cost-effectiveness of antipsychotics based on French observational data. PLAI was associated with the highest probability of being the optimal treatment from the French health insurance perspective.